Dianthus Q1 net loss $29.5M; gMG trial enrollment complete, top-line Sep 2025

Dianthus Therapeutics, Inc. /DE/

2025-Q1 EPS reported -$0.82 revenue$1,163,000

Net loss $29.5M ($0.82/sh) vs $13.7M ($0.54/sh) Q1 2024; cash $331.5M, runway into 2H'27.
Phase 2 MaGic gMG trial enrolled 65 patients; top-line results expected September 2025.
Phase 3 CAPTIVATE CIDP trial ongoing; interim responder analysis 2H'26.
Phase 2 MoMeNtum MMN trial ongoing; top-line results 2H'26.
Appointed John C. King as CCO and Sujay Kango to Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.